Hillsdale Investment Management Inc. Exelixis, Inc. Transaction History

Hillsdale Investment Management Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$20.17 - $23.93 $4,034 - $4,786	-200 Reduced 0.83%	24,000 $569,000
Q3 2023 Nov 09, 2023	BUY	$19.04 - $22.74 $460,768 - $550,308	24,200 New	24,200 $528,000
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $5,984 - $6,956	400 Added 1.56%	26,000 $417,000
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $434,256 - $576,684	24,900 Added 3557.14%	25,600 $533,000
Q1 2022 Apr 28, 2022	SELL	$17.03 - $22.67 $548,366 - $729,974	-32,200 Reduced 97.87%	700 $16,000
Q4 2021 Feb 07, 2022	SELL	$15.84 - $21.88 $55,440 - $76,580	-3,500 Reduced 9.62%	32,900 $602,000
Q3 2021 Oct 21, 2021	BUY	$16.3 - $21.14 $593,320 - $769,496	36,400 New	36,400 $770,000
Q1 2020 May 12, 2020	SELL	$14.46 - $21.8 $5,784 - $8,720	-400 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $7,840 - $9,904	400 New	400 $10,000
Q4 2017 Feb 13, 2018	SELL	$24.23 - $30.93 $1.4 Million - $1.79 Million	-57,900 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	57,900	57,900 $1.43 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.